A Phase 1, Randomized Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the H5-VLP + GLA-AF Pandemic Influenza Vaccine in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 18 Feb 2015
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary) ; Influenza A virus vaccine-H5N1 (Primary) ; Aluminium hydroxide; Glycopyranosyl lipid adjuvant; Glycopyranosyl lipid adjuvant
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions
- 18 Feb 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 17 Apr 2013 Interim results published in a Medicago media release and presented at the World Vaccine Congress.
- 09 Apr 2013 Positive interim results will be presented at the World Vaccine Congress.